reducing-targeting-noise-by-supplementing-claims-with-oncology-labs-1

CASE STUDY

Reducing targeting noise by supplementing claims with oncology labs: Metastatic breast cancer case study

In precision oncology, a diagnosis code can point you in the right direction, but it rarely tells the whole story. This case study shows how supplementing claims with oncology lab results can help you  reduce targeting noise and engage the right providers sooner.

What you'll learn:

  • Why claims-only targeting can create outsized provider lists when therapy eligibility depends on biomarker-defined subtypes

  • How syncing longitudinal claims with genomic lab results narrowed 75,395 metastatic breast cancer patients to 1,188 subtype-confirmed patients, and 9,168 oncologists to 340 actionable targets

  • Why genomic testing can create a critical window for field engagement before treatment decisions are made